A PHASE 2 OPEN LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF RECIFERCEPT IN CHILDREN WITH ACHONDROPLASIA

Recifercept

Recifercept

Recifercept

Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Severe AEs

Change From Baseline in Height at Month 24

Clearance (CL/F) of Recifercept

Change From Baseline in Sitting Height to Standing Height Ratio at Months 3, 6, 9

Change From Baseline in Arm Span to Height/Length Difference at Months 3, 6, 9

Change From Baseline in Knee Height to Lower Segment Ratio at Months 3, 6, 9

Change From Baseline in Occipito-Frontal Circumference at Months 3, 6, 9

Change From Baseline in Occipito-Frontal Distance to Occipito-mid-Face Measurements Ratio at Months 3, 6, 9

Change From Baseline in Z-Score for Occipito-frontal Circumference, Arm Span, Sitting Height and Skull Morphology at Months 3, 6, 9

Change From Baseline in Fixed Flexion Angles at Elbow at Months 3, 6, 9

Change From Baseline in Body Mass Index (BMI) at Months 3, 6, 9

Change From Baseline in Waist to Chest Circumference Ratio at Months 3, 6, 9

Number of Participants With Clinically Meaningful Findings in Laboratory Test Parameters Through the Study

Number of Participants With Clinically Significant Findings in Vital Signs Through the Study

Number of Participants With Clinically Significant Findings in Physical Examination Through the Study

Number of Participants With Positive Anti-Drug Antibodies (ADA)